Literature DB >> 18095894

Rheos Baroreflex Hypertension Therapy System to treat resistant hypertension.

Ingrid J M Scheffers1, Abraham A Kroon, Jan H M Tordoir, Peter W de Leeuw.   

Abstract

Resistant hypertension has a high prevalence and is associated with high morbidity and mortality. The Rheos Baroreflex Hypertension Therapy System is an implantable device that offers a completely new approach to treating patients with resistant hypertension by electrically activating the carotid baroreflex. Preliminary results from current feasibility clinical trials have shown sustained decreases in blood pressure after 1 year. The pivotal trial for US FDA approval and market release is currently ongoing. This article profiles the Rheos System and evaluates the treatment of resistant hypertension in general.

Entities:  

Mesh：

Year:  2008        PMID： 18095894     DOI： 10.1586/17434440.5.1.33

Source DB:  PubMed          Journal:  Expert Rev Med Devices        ISSN： 1743-4440            Impact factor:   3.166


  12 in total

Review 1.  [Anesthesia management in implantation of baroreceptor stimulators].

Authors:  T Werner; L Lebar; S Wittmann; A Keyser; M Fischer; J Schmidli; B M Graf; Y A Zausig
Journal:  Anaesthesist       Date:  2015-09       Impact factor: 1.041

2.  Effects of low-level carotid baroreflex stimulation on atrial electrophysiology.

Authors:  Mingyan Dai; Mingwei Bao; Jiafen Liao; Lilei Yu; Yanhong Tang; He Huang; Xi Wang; Congxin Huang
Journal:  J Interv Card Electrophysiol       Date:  2015-04-15       Impact factor: 1.900

Review 3.  Modulation of Sympathetic Overactivity to Treat Resistant Hypertension.

Authors:  Raven Voora; Alan L Hinderliter
Journal:  Curr Hypertens Rep       Date:  2018-09-07       Impact factor: 5.369

Review 4.  The role of the kidney and the sympathetic nervous system in hypertension.

Authors:  Philip Thomas; Indranil Dasgupta
Journal:  Pediatr Nephrol       Date:  2014-03-08       Impact factor: 3.714

Review 5.  Carotid baroreflex activation: past, present, and future.

Authors:  Ingrid J M Scheffers; Abraham A Kroon; Peter W de Leeuw
Journal:  Curr Hypertens Rep       Date:  2010-04       Impact factor: 5.369

Review 6.  Timing and efficacy of alternative methods of sympathetic blockade.

Authors:  Alexandros Briasoulis; George L Bakris
Journal:  Curr Hypertens Rep       Date:  2012-10       Impact factor: 5.369

Review 7.  The role of nonpharmacologic device interventions in the management of drug-resistant hypertension.

Authors:  William H Frishman; Daniel Glicklich
Journal:  Curr Atheroscler Rep       Date:  2014-05       Impact factor: 5.113

8.  Effect of selective vagal nerve stimulation on blood pressure, heart rate and respiratory rate in rats under metoprolol medication.

Authors:  Mortimer Gierthmuehlen; Dennis T T Plachta
Journal:  Hypertens Res       Date:  2015-11-19       Impact factor: 3.872

9.  What price for blood pressure control?

Authors:  Stephen C Textor
Journal:  J Clin Hypertens (Greenwich)       Date:  2009-10       Impact factor: 3.738

Review 10.  Therapeutic perspectives in hypertension: novel means for renin-angiotensin-aldosterone system modulation and emerging device-based approaches.

Authors:  Thomas Unger; Ludovit Paulis; Domenic A Sica
Journal:  Eur Heart J       Date:  2011-09-27       Impact factor: 29.983
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.